Feed RZLT
RZ

Rezolute, Inc. RZLT · NASDAQ

$3.58 -8.21% (-$0.32)

Market cap
$375.5M
Enterprise value
$364.9M
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
-82.4%
Gross margin
-
Net margin
-
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.61
Free float
63.0%

About the company

Rezolute, Inc. (RZLT) is a biotechnology company specializing in the development of therapeutics to improve the lives of patients suffering from metabolic disorders and endocrine disorders. Headquartered in the United States, the company focuses on researching and developing new treatment approaches and therapies for patients with type 1 diabetes and other health issues. The company concentrates on innovations in pharmacology and therapeutic methods, working to create new drugs that can enhance the quality of life for affected patients. Shares of Rezolute, Inc. (RZLT) can be an appealing choice for investors seeking investment opportunities in the biotechnology and healthcare research sector.

Sector

Healthcare

Industry

Biotechnology

CEO

Nevan Charles Elam

Employees

58

Headquarters

Redwood City

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.